• 1. Emerging investigator series: kinetics of diopside reactivity for carbon mineralization in mafic–ultramafic rocks
  BrianaAguila,LandonHardee,H.ToddSchaef,SiavashZare,MohammadJavadAbdolhosseiniQomi,JarrodV.Crum,JadeE.HollimanJr.,ElenaTajueloRodriguez,LawrenceM.Anovitz,KevinM.Rosso,QuinR.S.Miller
• 2. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 3. Enantiomorphic symmetry breaking in crystallization of molten sodium chlorate?
  Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636
• 4. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 5. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555

Introduction to 3-(2-Fluoro-6-nitrophenyl)propanoic acid (CAS No. 132715-74-3)

3-(2-Fluoro-6-nitrophenyl)propanoic acid, identified by the Chemical Abstracts Service Number (CAS No.) 132715-74-3, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound, featuring a fluoro-substituted nitrophenyl group linked to a propanoic acid moiety, exhibits unique structural and chemical properties that make it a valuable intermediate in the synthesis of various bioactive molecules. The presence of both fluorine and nitro functional groups imparts distinct electronic and steric characteristics, influencing its reactivity and potential applications in drug discovery.

The fluoro substituent at the 2-position of the phenyl ring is a key feature, as fluorine atoms are well-known for their ability to modulate metabolic stability, binding affinity, and pharmacokinetic profiles of pharmaceutical compounds. In particular, fluorine atoms can enhance lipophilicity, improve binding interactions with biological targets, and prolong the half-life of drugs by resisting enzymatic degradation. The nitrophenyl group at the 6-position introduces a strong electron-withdrawing effect, which can influence the electronic distribution across the molecule and affect its solubility and reactivity. This combination of substituents makes 3-(2-Fluoro-6-nitrophenyl)propanoic acid a versatile building block for designing novel therapeutic agents.

In recent years, there has been growing interest in the development of small-molecule inhibitors targeting various enzymatic and receptor systems. 3-(2-Fluoro-6-nitrophenyl)propanoic acid has been explored as a precursor in the synthesis of compounds with potential applications in oncology, immunology, and anti-inflammatory therapies. Its structural framework allows for modifications at multiple positions, enabling chemists to fine-tune properties such as potency, selectivity, and pharmacokinetic behavior. For instance, derivatives of this compound have been investigated for their ability to inhibit kinases and other enzymes involved in cancer progression.

One notable area of research involves the use of 3-(2-Fluoro-6-nitrophenyl)propanoic acid in the development of kinase inhibitors. Kinases are enzymes that play crucial roles in cell signaling pathways, and their dysregulation is often associated with diseases such as cancer. By designing molecules that selectively inhibit specific kinases, researchers aim to develop treatments that disrupt aberrant signaling networks without affecting normal cellular processes. The fluoro and nitro groups in 3-(2-Fluoro-6-nitrophenyl)propanoic acid provide opportunities for optimizing binding interactions with kinase active sites. For example, computational studies have suggested that fluorine substitution can enhance binding affinity by improving hydrophobic interactions or by stabilizing specific conformational states of the target enzyme.

Additionally, the propanoic acid moiety offers a handle for further functionalization, allowing for the introduction of additional pharmacophores or for linking to other molecular fragments. This flexibility makes 3-(2-Fluoro-6-nitrophenyl)propanoic acid a valuable scaffold for structure-based drug design. Researchers often employ high-throughput screening methods combined with molecular modeling techniques to identify promising derivatives with enhanced biological activity. Such approaches have led to the discovery of several lead compounds that are now being evaluated in preclinical studies.

The pharmaceutical industry has also shown interest in using 3-(2-Fluoro-6-nitrophenyl)propanoic acid as a starting material for synthesizing protease inhibitors. Proteases are enzymes that cleave peptide bonds and are involved in various physiological processes, including inflammation and infection. Inhibiting specific proteases has been successful in treating conditions such as HIV/AIDS and arthritis. The unique combination of functional groups in 3-(2-Fluoro-6-nitrophenyl)propanoic acid allows for the design of molecules that can interact with protease active sites through multiple non-covalent interactions. This has led to the development of novel inhibitors with improved efficacy and reduced side effects compared to existing therapies.

In conclusion, 3-(2-Fluoro-6-nitrophenyl)propanoic acid (CAS No. 132715-74-3) represents a significant advancement in medicinal chemistry due to its versatile structural features and potential applications in drug development. Its ability to serve as a precursor for kinase inhibitors, protease inhibitors, and other bioactive molecules underscores its importance in modern pharmaceutical research. As our understanding of disease mechanisms continues to evolve, compounds like 3-(2-Fluoro-6-nitrophenyl)propanoic acid will remain at the forefront of efforts to discover new treatments that improve human health.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)